Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer

Cancer Investigation

Volumn 19, Issue 2, 2001, Pages 137-144

  Razis, E ^a   Dimopoulos, A M ^a   Bafaloukos, D ^a   Papadimitriou, C ^a   Kalogera Fountzila, A ^a   Kalofonos, H ^a   Briassoulis, E ^a   Samantas, E ^a   Keramopoulos, A ^a   Pavlidis, N ^a   Kosmidis, P ^a   Fountzilas, G ^a  

^a Hellenic Cooperative Oncology Group   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DISEASE COURSE; DOSE RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GREECE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 0035081889     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100000148     Document Type: Article

References (21)

1. Drugs ten years later: Epirubicin
2. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion
3. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for Metastatic Breast Cancer
4. Paclitaxel in Metastatic Breast Cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
5. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
6. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated Metastatic Breast Cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
7. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
8. Evolving concepts in the systemic drug therapy of breast cancer
9. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes. A feasibility study
10. Intensive chemotherapy with high-dose epirubicin every two weeks and prophylactic administration of filgastrim. A phase II study
11. Toxicity and response criteria of the eastern cooperative oncology group
12. Non parametric estimation from incomplete observations
13. A randomized study of epirubicin monotherapy every 4 or every 2 weeks in advanced breast cancer
14. A phase II study of doxorubicin/paclitaxel plus G-CSF for Metastatic Breast Cancer
15. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer
16. Phase I study of paclitaxel and epirubicin in patients with Metastatic Breast Cancer: A preliminary report on safety
17. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer
18. A phase II study. Paclitaxel and epirubicin as first line chemotherapy for patients with Metastatic Breast Cancer
19. Paclitaxel plus anthracycline as first line chemotherapy for breast cancer patients: The Italian experience. Rationale for paclitaxel maintenance therapy
20. 12 Cycles of paclitaxel immediately following high dose chemotherapy with autologous stem cell transplantation can induce complete remissions in patients with advanced breast and ovarian carcinoma
21. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A+T) as first line therapy for Metastatic Breast Cancer (MBC): An intergroup trial